Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90 Y Radioembolization with Immunotherapy in HCC
New strategies combining yttrium 90 ( 90 Y) radioembolization and immune checkpoint inhibitor therapy for treatment of advanced-stage hepatocellular carcinoma show promising safety and improved tumor response rates, with 90 Y radioembolization modulating the tumor immune microenvironment and enhancing responsiveness to immunotherapy.
Authors
- Beau B. Toskich (ORCID: https://orcid.org/0000-0003-4707-7921)
- S. Cheenu Kappadath (ORCID: https://orcid.org/0000-0003-4643-7745)
- Sunil Krishnan (ORCID: https://orcid.org/0000-0002-1340-4771)
- Rony Avritscher (ORCID: https://orcid.org/0000-0002-5122-3445)
- Mishal Mendiratta‐Lala (ORCID: https://orcid.org/0000-0003-4055-916X)
- Valerie Chew (ORCID: https://orcid.org/0000-0002-5617-0936)
- Ghassan K. Abou‐Alfa (ORCID: https://orcid.org/0000-0002-1522-8054)
- T. Gade (ORCID: https://orcid.org/0000-0001-8783-0661)
- Riad Salem (ORCID: https://orcid.org/0000-0001-9745-1825)
- Edward Kim (ORCID: https://orcid.org/0000-0001-8050-2366)
- Ahmed Kaseb
Institutions
- Northwestern University (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- SingHealth (SG)
- Trinity College Dublin (IE)
- Cornell University (US)
- University of Michigan (US)
- Jacksonville College (US)
- Northwestern Medicine (US)
- University of Pennsylvania (US)
- The University of Texas Health Science Center at Houston (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Radiology
- Published
- 2026-09-01
- DOI
- https://doi.org/10.1148/radiol.251415
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Cancer Society